

Forwarding address

Page 1 of 1

Debbie Parsons

From: Debbie Parsons
Sent: Monday, September 25, 2006 3:15 PM
To: Dolores Rice
Subject: RE: Forwarding address
Attachments: [REDACTED].doc

Hi Delores

I am enclosed this lady's original letter as Dr. Laing may want to change the dates in the letter.
Debbie

From: Dolores Rice [mailto:Dolores.Rice@easternhealth.ca]
Sent: September 21, 2006 2:45 PM
To: debbie.parsons@hccsj.nl.ca
Subject: Forwarding address

Hi Debbie - forwarding address on [REDACTED] MCP: [REDACTED]

[REDACTED]

Phone #: [REDACTED]

This was last updated at the [REDACTED] on Sept. 23/04 when the pt. contacted them for release of authorization.

Dolores

6/14/2007

SPOKE TO [REDACTED] - PT. LEFT PROVINCE IN 2001 - NO
FORWARDING ADDRESS
March 6, 2006

RE: [REDACTED]
MCP #: [REDACTED]

Ms. [REDACTED] was diagnosed in 1997 with a carcinoma of the *left* breast. The original report of the estrogen and progesterone receptors showed <5% staining for estrogen and negative staining for progesterone. A repeat report from Mount Sinai Hospital has shown the tumour to be estrogen and progesterone receptor positive at 50% and <1% respectively.

Ms. [REDACTED] subsequently developed a left axillary recurrence in 2001. The original report of the estrogen and progesterone receptors showed negative staining for estrogen and <10% staining for progesterone. A repeat report from Mount Sinai Hospital has shown the tumour to be estrogen and progesterone receptor positive at 95% and 0% respectively.

This patient was discussed at the Physician Review Panel on March 4, 2006. The recommendation of the Panel is that this lady should be offered treatment with Tamoxifen. If Tamoxifen is contraindicated or not tolerated, an Aromatase inhibitor may be used in post menopausal patients.

If you wish, this patient may be referred to one of the Medical Oncologists at The Dr. H. Bliss Murphy Cancer Center for further evaluation.

We would ask that you communicate this information to your patient as soon as possible.

Yours sincerely,

Kara Laing, M.D., F.R.C.P. (C)
Clinical Chief, Cancer Care Program
The Dr. H. Bliss Murphy Cancer Center

Cc: [REDACTED]